Los Angeles Capital Management’s Procept Biorobotics PRCT Stock Holding History

Los Angeles Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.1K	Sell	284 -5,672	-95%	-$160K	﹤0.01%	2025
2025 Q4	$205K	Buy	+5,956	New	+$198K	﹤0.01%	1234
2025 Q3	–	Sell	-13,832	Closed	-$797K	–	1505
2025 Q2	$797K	Sell	13,832 -15,863	-53%	-$897K	﹤0.01%	714
2025 Q1	$1.73M	Buy	29,695 +16,715	+129%	+$1.14M	0.01%	432
2024 Q4	$1.05M	Buy	12,980 +8,399	+183%	+$718K	﹤0.01%	605
2024 Q3	$367K	Buy	+4,581	New	+$325K	﹤0.01%	950

Other funds holding PRCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Los Angeles Capital Management's PRCT Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Procept Biorobotics (PRCT) stake by 95% in Q1 2026, selling an estimated $160K and leaving 284 shares worth $7.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Los Angeles Capital Management first reported a position in PRCT in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.73M in Q1 2025. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

Los Angeles Capital Management held 284 shares of Procept Biorobotics worth $7.1K as of Q1 2026.
Los Angeles Capital Management sold 5,672 Procept Biorobotics shares in Q1 2026, an estimated $160K.
Procept Biorobotics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2025 holding.
Los Angeles Capital Management first reported a position in Procept Biorobotics in Q3 2024 and has held it in 6 quarters since.
Los Angeles Capital Management's Procept Biorobotics position peaked at $1.73M in Q1 2025.
256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.